Illumina, Inc. vs Illinois Tool Works Inc. — how do they compare? Illumina, Inc. trades at $278.17 (market cap $39.95B), while Illinois Tool Works Inc. trades at $264.13 (market cap $74.38B). The key difference: Illinois Tool Works Inc. is the larger of the two by market cap, and Illinois Tool Works Inc. pays a 2.63% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Illinois Tool Works Inc. for 67 Days on average.
| ILMN | ITW | |
|---|---|---|
Market Cap | $39.95B | $74.38B |
Volume | 3,169,503 | 1,125,477 |
Sector | Health | Industrials |
52-Week High | $293.69 | $299.60 |
52-Week Low | $91.00 | $241.07 |
Typical Hold Time | 83 Days | 67 Days |
Enterprise Value | $41.31B | $83.23B |
Dividend Yield | — | 2.63% |
Signals from Pluang's Aura AI — not financial advice
ILMN trades at $264.40, down 1.25% on the day, but remains near its recent 52-week high of $278.99 (Defense World, 2026-10-01). The stock has surged 94.9% year-to-date (Zacks Investment Research, 2026-09-24), supported by strong earnings beats in recent quarters and a bullish technical trend. Fundamentals show a significant turnaround, with 2025 net income reaching $850 million after prior losses, though valuation ratios like a P/E of 49.36 are elevated. The pending inclusion in the S&P 500 (PRNewsWire, 2026-09-04) adds a positive catalyst.
The outlook is positive, driven by sequencing growth, AI integration in genomics, and improved profitability. However, risks include high valuation sensitivity, cost volatility, and competitive pressures in the life sciences sector. Analyst consensus is bullish with a 54% buy rating, but the average price target of $241 suggests limited near-term upside from current levels.
ITW trades at $264.71, up 1.36% today, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $2.84, beating estimates, and maintains robust profitability with a 19.39% net income margin and 104.65% ROE. Recent news highlights its dividend increase to $1.72 per share and its status as a Dividend King with 59 years of consecutive increases.
The outlook is mixed: strong cash flow and dividend reliability support income investors, but high valuation ratios (P/E 23.65, P/B 25.7) and bearish technicals suggest near-term pressure. Risks include debt levels and sector volatility, while analyst consensus leans hold with a $276.86 price target.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →